Moderna Inc. logo

Moderna Inc. (0A45)

Market Closed
27 Jun, 15:30
$
27. 38
+0.35
+1.3%
$
- Market Cap
- P/E Ratio
0% Div Yield
7,423 Volume
-13.23 Eps
$ 27.02
Previous Close
Day Range
27.1 27.86
Year Range
23.16 129.21
Want to track 0A45 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 35 days

Summary

0A45 closed Friday higher at $27.37, an increase of 1.3% from Thursday's close, completing a monthly decrease of -2.93% or $0.82. Over the past 12 months, 0A45 stock lost -34.24%.
0A45 is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.96%, based on the last three reports. The next scheduled earnings report is due on Aug 07, 2025.
Moderna Inc. has completed 1 stock splits, with the recent split occurring on Aug 03, 2017.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

0A45 Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
Moderna Stock Gains on Encouraging Flu Vaccine Data

Moderna Stock Gains on Encouraging Flu Vaccine Data

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

Zacks | 1 day ago
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine

Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine

The biotechnology company's messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Wsj | 2 days ago
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna to apply for approval of its standalone flu vaccine, called mRNA-1010, later this year.

Cnbc | 2 days ago

Moderna Inc. Dividends

0A45 is not paying dividends to its shareholders.

Moderna Inc. Earnings

7 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
20 Feb 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
0.03
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS
0A45 is not paying dividends to its shareholders.
7 Aug 2025 (In 1 month) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
20 Feb 2025 Date
-
Cons. EPS
-
EPS
7 Nov 2024 Date
-
Cons. EPS
0.03
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS

Moderna Inc. (0A45) FAQ

What is the stock price today?

The current price is $27.38.

On which exchange is it traded?

Moderna Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is 0A45.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, no market cap data is available.

When is the next earnings date?

The next earnings report will release on Aug 07, 2025.

Has Moderna Inc. ever had a stock split?

Moderna Inc. had 1 splits and the recent split was on Aug 03, 2017.

Moderna Inc. Profile

Biotechnology Industry
Healthcare Sector
Stephane Bancel CEO
LSE Exchange
US60770K1079 ISIN
US Country
5,800 Employees
- Last Dividend
- Last Split
7 Dec 2018 IPO Date

Overview

Moderna, Inc., is a pioneering biotechnology firm founded in 2010, with its headquarters located in Cambridge, Massachusetts. Initially known as Moderna Therapeutics, Inc., the company rebranded to Moderna, Inc. in August 2018. It specializes in leveraging messenger RNA (mRNA) technology to develop, discover, and commercialize therapeutics and vaccines for a wide array of diseases. These diseases range from infectious diseases, immuno-oncology, rare diseases, to autoimmune and cardiovascular diseases. Moderna's operations span across the United States, Europe, and globally. The company has established strategic alliances and collaborations with notable entities in the biotech and pharmaceutical industry, including AstraZeneca, Merck & Co., Inc, Vertex Pharmaceuticals, Chiesi Farmaceutici S.p.A., and The Bill & Melinda Gates Foundation, among others.

Products and Services

  • Respiratory Vaccines

    Moderna's respiratory portfolio includes vaccines against COVID-19, influenza, and respiratory syncytial virus. The company utilizes its mRNA technology to develop vaccines like Spikevax, as well as its hMPV/PIV3 vaccine candidates, targeting multiple respiratory pathogens.

  • Latent Vaccines

    The latent vaccines developed by Moderna target a variety of viruses such as the cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella zoster virus, and the human immunodeficiency virus. These vaccines aim to provide immunity against viruses that remain dormant in the body and can cause disease upon reactivation.

  • Public Health Vaccines

    Moderna's public health vaccines include projects against diseases like Zika, Nipah, and Mpox. These vaccines are part of Moderna's commitment to addressing emerging public health threats and pandemics with swift vaccine development.

  • Infectious Diseases Vaccines

    Vaccines against Lyme disease and norovirus fall under this category. Moderna leverages its mRNA platform to create vaccines designed to protect against widespread and challenging infectious diseases.

  • Systemic Secreted and Cell Surface Therapeutics

    This innovative category includes therapies that are administered systemically to target secreted and cell surface proteins, leveraging mRNA technology for treating various conditions beyond infectious diseases, including potential treatments for autoimmune and cardiovascular diseases.

  • Cancer Vaccines

    Moderna's oncology portfolio includes personalized cancer vaccines, KRAS vaccines, and checkpoint vaccines. These products represent an extension of mRNA technology into the field of immuno-oncology, targeting the immune system to fight cancer.

  • Intratumoral Immuno-Oncology Products

    These are innovative treatments administered directly into tumors to elicit a more potent and localized immune response against cancer. They form part of Moderna's broader strategy to harness the body's immune system in combating cancer.

  • Rare Disease Intracellular Therapeutics

    Moderna is developing therapies for rare diseases by targeting intracellular mechanisms. These therapeutics are designed to address genetic disorders and diseases with limited treatment options.

  • Inhaled Pulmonary Therapeutics

    The company is also exploring the potential of inhaled therapies for diseases affecting the lungs, utilizing its mRNA technology to create novel treatments for pulmonary conditions.

Contact Information

Address: 200 Technology Square
Phone: 617 714 6500